Results 161 to 170 of about 92,511 (354)

Crystallization Scale Preparation of a Stable GPCR Signaling Complex between Constitutively Active Rhodopsin and G-Protein

, 2014
Shoji Maeda, Dawei Sun, Ankita Singhal, Marcello Foggetta, Georg H. Schmid, J. Standfuss, Michael Hennig, Roger Dawson, Dmitry B. Veprintsev, Gebhard F. X. Schertler   +9 more
openalex   +2 more sources

Regulation of GPCR activity, trafficking and localization by GPCR‐interacting proteins [PDF]

, 2011
Ana C. Magalhães, Henry A. Dunn, Stephen S. G. Ferguson   +2 more
openalex   +1 more source

Pharmacogenomics of GPCR Drug Targets

Cell, 2018
A. Hauser, A. Hauser, S. Chavali, I. Masuho, L. Jahn, K. Martemyanov, David E. Gloriam, M. Babu   +7 more
semanticscholar   +1 more source

The Oxytocin Receptor in Spermatozoa May Originate From Both Spermatogenesis and Epididymal Maturation, and Regulates Capacitation

Andrology, EarlyView.
Abstract Background The oxytocin receptor (OR) is a G‐protein‐coupled receptor recently identified in human spermatozoa, whose origin and role in sperm physiology remain unknown. Objectives In this study, using the pig as a model, we examine the presence of the OR in ejaculated spermatozoa through immunofluorescence and immunoblotting, and investigate ...
Jesús Martínez‐Hernández, Ferran Garriga, Adeel Ahmad, Lorena Padilla, Carolina Maside, Sergi Bonet, Isabel Barranco, Jordi Roca, Luis Miguel Pastor, Marc Yeste   +9 more
wiley   +1 more source

Luciferase Reporter Assay System for Deciphering GPCR Pathways [PDF]

, 2010
Zhi-jie Jey Cheng, Denise Garvin, Aileen Paguio, Pete Stecha, Keith V. Wood, Frank Fan   +5 more
openalex   +1 more source

Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis [PDF]

, 2022
Souvik Banerjee, Sue-Chin Lee, Derek D. Norman, Gábor Tigyi   +3 more
openalex   +1 more source

Artificial intelligence streamlines scientific discovery of drug–target interactions

British Journal of Pharmacology, EarlyView.
Abstract Drug discovery is a complicated process through which new therapeutics are identified to prevent and treat specific diseases. Identification of drug–target interactions (DTIs) stands as a pivotal aspect within the realm of drug discovery and development. The traditional process of drug discovery, especially identification of DTIs, is marked by
Yuxin Yang, Feixiong Cheng
wiley   +1 more source

Disabling Gβγ SNARE interaction in transgenic mice disrupts GPCR-mediated presynaptic inhibition leading to physiological and behavioral phenotypes [PDF]

, 2018
Zack Zurawski, Analisa D. Thompson Gray, Lillian J. Brady, Brian Page, Emily Church, Nicholas A. Harris, Michael R. Dohn, Yun Young Yim, Karren Hyde, Douglas P. Mortlock, Danny G. Winder, Simon Alford, Carrie K. Jones, Heidi E. Hamm   +13 more
openalex   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source